• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Innovative drug treatments for viral and autoimmune myocarditis.
【24h】

Innovative drug treatments for viral and autoimmune myocarditis.

机译：病毒性和自身免疫性心肌炎的创新药物治疗。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Myocarditis has been shown to be a common cause of cardiomyopathy and is believed to account for 25% of all cases in human beings. Unfortunately, the disease is difficult to detect before a myopathic process ensues. Treatment of myocarditis-induced heart failure includes the standard regimen of diuretics, digoxin, angiotensin-converting enzyme inhibitors, and currently, beta-adrenergic blockers. Treatment of myocarditis itself is dependent on the etiology of the illness. Treatments under investigation include immunosuppressants, nonsteroidal antiinflammatory agents, immunoglobulins, immunomodulation, antiadrenergics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, nitric oxide inhibition (e.g., aminoguanidine), and antiviral agents. Despite advances in treatment, more work needs to be done in the early detection of myocarditis. Additionally, better means need to be established for distinguishing between viral and autoimmune forms of the disease, so that appropriate treatment can be instituted.
机译：心肌炎已被证明是心肌病的常见病因，据信占人类所有病例的25％。不幸的是，这种疾病很难在肌病过程发生之前被发现。心肌炎引起的心力衰竭的治疗包括利尿剂，地高辛，血管紧张素转化酶抑制剂和目前的β-肾上腺素能阻滞剂的标准治疗方案。心肌炎本身的治疗取决于疾病的病因。正在研究的治疗方法包括免疫抑制剂，非甾体抗炎药，免疫球蛋白，免疫调节，抗肾上腺素能，钙通道阻滞剂，血管紧张素转化酶抑制剂，一氧化氮抑制作用（例如氨基胍）和抗病毒剂。尽管治疗取得了进步，但在早期发现心肌炎方面仍需要做更多的工作。另外，需要建立更好的方法来区分疾病的病毒形式和自身免疫形式，以便可以采取适当的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号